C. Costoya

Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

I. Amit, Eyal David, S. Quezada, 2022, Nature Cancer.

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

S. Iacobelli, J. Vicencio, S. Ameer-Beg, 2022, Cell Death & Disease.

Fcγ receptors and immunomodulatory antibodies in cancer

S. Quezada, K. Peggs, F. Gálvez-Cancino, 2023, Nature reviews. Cancer.